Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical study for HXP056, its oral multi‑selective therapy for hemorrhagic retinal diseases, following successful completion of Phase I in Chinese patients with wet age‑related macular degeneration (wAMD) – advancing a first‑in‑class oral candidate designed to penetrate the blood‑retinal barrier and address multiple retinal vascular indications.
Haixi Pharma Innovation Validation: HXP056 demonstrates platform‑based R&D capabilities (MultiSel‑Opt); oral BRB penetration technical differentiation vs. domestic ophthalmology peers (concentrated in biosimilars); progression to Phase II validates Phase I safety and PK profile.
Clinical Development Trajectory: Phase II wAMD efficacy data 2027‑2028; DME and RVO expansion cohorts 2028‑2029; potential for China‑first approval 2029‑2030 assuming positive efficacy; global partnership (US/EU rights) likely upon Phase II data with estimated US$200‑400 million upfront value.
Technical Risk/Benefit: Blood‑retinal barrier penetration historically challenging for small molecules; HXP056’s optimized systemic exposure suggests favorable therapeutic index; multi‑selective mechanism may increase efficacy but also off‑target risk – Phase II safety monitoring critical.
Competitive Response: Novartis (NOV1801), Roche (oral anti‑VEGF in development) represent Big Pharma competition; Haixi Bio’s China‑first development and cost‑efficient clinical execution may enable earlier market entry vs. global peers; NRDL pricing (~RMB5,000‑8,000 annually) likely required for volume access.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II efficacy expectations, indication expansion timelines, and commercial potential for HXP056. Actual results may differ due to blood‑retinal barrier penetration variability, competitive dynamics with intravitreal anti‑VEGF therapies, and regulatory requirements for novel oral retinal therapeutics.-Fineline Info & Tech
By Fineline Cube